Related references
Note: Only part of the references are listed.Antisense Oligonucleotides As Potential Therapeutics for Type 2 Diabetes
Suxiang Chen et al.
NUCLEIC ACID THERAPEUTICS (2021)
A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in CombinationWith Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Vincent Ribrag et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)
Emerging therapies for rare cutaneous cancers: A systematic review
Andrew Garcia et al.
CANCER TREATMENT REVIEWS (2021)
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia
Valentina Bardelli et al.
GENES CHROMOSOMES & CANCER (2021)
Antisense technology: A review
Stanley T. Crooke et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2021)
Overcoming the challenges of tissue delivery for oligonucleotide therapeutics
Tufan Gokirmak et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2021)
The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
Maria Gagliardi et al.
BIOMEDICINES (2021)
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Alison R. Walker et al.
BLOOD ADVANCES (2021)
Evaluation of DNA segments in 2′-modified RNA sequences in designing efficient splice switching antisense oligonucleotides
Bao T. Le et al.
RSC ADVANCES (2021)
Aptamers and Antisense Oligonucleotides for Diagnosis and Treatment of Hematological Diseases
Valentina Giudice et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Alpha-l-Locked Nucleic Acid-Modified Antisense Oligonucleotides Induce Efficient Splice Modulation In Vitro
Prithi Raguraman et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Roles and mechanisms of alternative splicing in cancer - implications for care
Sophie C. Bonnal et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2020)
Novel Disulfide-Bridged Bioresponsive Antisense Oligonucleotide Induces Efficient Splice Modulation in Muscle Myotubes in Vitro
Bao T. Le et al.
ACS OMEGA (2020)
The Long and the Short of BRD4: Two Tales in Breast Cancer
Sicong Zhang et al.
MOLECULAR CELL (2020)
Advances in oligonucleotide drug delivery
Thomas C. Roberts et al.
NATURE REVIEWS DRUG DISCOVERY (2020)
Therapeutic Antisense Oligonucleotides Are Coming of Age
C. Frank Bennett
ANNUAL REVIEW OF MEDICINE, VOL 70 (2019)
Exosome-based antisense locked nucleic acid delivery for inhibition of type II collagen degradation in chondrocyte
Kyeongsoo Jeong et al.
JOURNAL OF INDUSTRIAL AND ENGINEERING CHEMISTRY (2019)
Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics
Bao T. Le et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2019)
Light-Triggered Cellular Delivery of Oligonucleotides
Leena-Stiina Kontturi et al.
PHARMACEUTICS (2019)
Downregulation of TdT Expression through Splicing Modulation by Antisense Peptide Nucleic Acid (PNA)
Soheila Montazersaheb et al.
CURRENT PHARMACEUTICAL BIOTECHNOLOGY (2019)
Systematic evaluation of 2′-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro
Suxiang Chen et al.
SCIENTIFIC REPORTS (2019)
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial
David R. Spigel et al.
ONCOLOGIST (2019)
PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
Mark Roschewski et al.
BLOOD (2019)
Current overview on the clinical update of Bcl-2 anti-apoptotic inhibitors for cancer therapy
Vasanti Suvarna et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Evaluation of a locked nucleic acid form of antisense oligo targeting HIF-1α in advanced hepatocellular carcinoma
Jennifer Wu et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2019)
A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer
Evan Y. Yu et al.
INVESTIGATIONAL NEW DRUGS (2018)
A phase I pharmacokinetic and pharmacodynamic study of GTI-2040 in combination with gemcitabine in patients with solid tumors
Laeeq Malik et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
The macrophage as a Trojan horse for antisense oligonucleotide delivery
James S. Novak et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2018)
Splicing mutations in human genetic disorders: examples, detection, and confirmation
Anna Abramowicz et al.
JOURNAL OF APPLIED GENETICS (2018)
Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics
Laura M. Urbanski et al.
WILEY INTERDISCIPLINARY REVIEWS-RNA (2018)
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial
Maro Ohanian et al.
LANCET HAEMATOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial.
Matthew J. Reilley et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Aberrant RNA Splicing in Cancer and Drug Resistance
Bi-Dar Wang et al.
CANCERS (2018)
The Cancer Spliceome: Reprograming of Alternative Splicing in Cancer
Ettaib El Marabti et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2018)
Cell-Penetrating Peptides to Enhance Delivery of Oligonucleotide-Based Therapeutics
Graham McClorey et al.
BIOMEDICINES (2018)
The Use of Tricyclo-DNA Oligomers for the Treatment of Genetic Disorders
Philippine Aupy et al.
BIOMEDICINES (2018)
Epigenetic therapy in urologic cancers: an update on clinical trials
Ines Faleiro et al.
ONCOTARGET (2017)
Spinraza-a rare disease success story
V. Prakash
GENE THERAPY (2017)
Clinical pharmacology and clinical trials of ribonucleotide reductase inhibitors: is it a viable cancer therapy?
Mukundan Baskar Mannargudi et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Borealis-2: A randomized phase II study of OGX-427 (apatorsen) plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial cancer (mUC) (Hoosier Cancer Research Network GU12-160).
Toni K. Choueiri et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Custirsen in combination with docetaxel and prednisone for patients with metastatic castration-resistant prostate cancer (SYNERGY trial): a phase 3, multicentre, open-label, randomised trial
Kim N. Chi et al.
LANCET ONCOLOGY (2017)
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial
Andrew H. Ko et al.
ONCOLOGIST (2017)
In vitro and in vivo delivery of therapeutic proteins using cell penetrating peptides
Azam Bolhassani et al.
PEPTIDES (2017)
Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS
Sarah J. Ross et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Acute lymphoblastic leukemia: a comprehensive review and 2017 update
T. Terwilliger et al.
BLOOD CANCER JOURNAL (2017)
Antisense oligonucleotide modified with serinol nucleic acid (SNA) induces exon skipping in mdx myotubes
Bao T. Le et al.
RSC ADVANCES (2017)
Nucleobase-modified antisense oligonucleotides containing 5-(phenyltriazol)-2′-deoxyuridine nucleotides induce exon-skipping in vitro
Bao T. Le et al.
RSC ADVANCES (2017)
Efficient SMN Rescue following Subcutaneous Tricyclo-DNA Antisense Oligonucleotide Treatment
Valerie Robin et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Rational Design of Short Locked Nucleic Acid-Modified 2′-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro
Bao T. Le et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model
Karima Relizani et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Antisense oligonucleotide-mediated MDM4 exon 6 skipping impairs tumor growth
Michael Dewaele et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
A phase I dose-escalation study of apatorsen (OGX-427), an antisense inhibitor targeting heat shock protein 27 (Hsp27), in patients with castration-resistant prostate cancer and other advanced cancers
K. N. Chi et al.
ANNALS OF ONCOLOGY (2016)
Therapeutic nucleic acids: current clinical status
Kannan Sridharan et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Exon Skipping Therapy
Courtney S. Young et al.
CELL (2016)
Evaluation of anhydrohexitol nucleic acid, cyclohexenyl nucleic acid and D-altritol nucleic acid-modified 2′-O-methyl RNA mixmer antisense oligonucleotides for exon skipping in vitro
Bao T. Le et al.
CHEMICAL COMMUNICATIONS (2016)
A phase I dose escalation, safety and pharmacokinetic (PK) study of AZD5312 (IONIS-ARRx), a first-in-class Generation 2.5 antisense oligonucleotide targeting the androgen receptor (AR)
S. Chowdhury et al.
EUROPEAN JOURNAL OF CANCER (2016)
Aberrant splicing of the DMP1-ARF-MDM2-p53 pathway in cancer
Kazushi Inoue et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
The Medicinal Chemistry of Therapeutic Oligonucleotides
W. Brad Wan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
A phase I pharmacodynamic study of GTI-2040, an antisense oligonucleotide against ribonuclotide reductase, in acute leukemias: a California Cancer Consortium study
Mark H. Kirschbaum et al.
LEUKEMIA & LYMPHOMA (2016)
Synthesis of a Morpholino Nucleic Acid (MNA)-Uridine Phosphoramidite, and Exon Skipping Using MNA/2′-O-Methyl Mixmer Antisense Oligonucleotide
Suxiang Chen et al.
MOLECULES (2016)
Acute myeloid leukemia: a comprehensive review and 2016 update
I. De Kouchkovsky et al.
BLOOD CANCER JOURNAL (2016)
Investigation of twisted intercalating nucleic acid (TINA)-modified antisense oligonucleotides for splice modulation by induced exon-skipping in vitro
Bao T. Le et al.
RSC ADVANCES (2016)
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
Nathalie M. Goemans et al.
PLOS ONE (2016)
DMP1β, a splice isoform of the tumour suppressor DMP1 locus, induces proliferation and progression of breast cancer
Dejan Maglic et al.
JOURNAL OF PATHOLOGY (2015)
Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
Aurelie Goyenvalle et al.
NATURE MEDICINE (2015)
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Clusterin: Review of research progress and looking ahead to direction in hepatocellular carcinoma
Peng Xiu et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2015)
First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer
A. G. de Liano et al.
BRITISH JOURNAL OF CANCER (2014)
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors
Woondong Jeong et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia
Rebecca B. Klisovic et al.
LEUKEMIA & LYMPHOMA (2014)
Dacarbazine with or without oblimersen (a Bcl-2 antisense oligonucleotide) in chemotherapy-naive patients with advanced melanoma and low-normal serum lactate dehydrogenase: 'The AGENDA trial'
Agop Y. Bedikian et al.
MELANOMA RESEARCH (2014)
Overexpression of Wilms Tumor 1 Gene as a Negative Prognostic Indicator in Acute Myeloid Leukemia
Xiaodong Lyu et al.
PLOS ONE (2014)
Exon-Skipping Antisense Oligonucleotides to Correct Missplicing in Neurogenetic Diseases
Kavitha Siva et al.
NUCLEIC ACID THERAPEUTICS (2014)
Exosomes are endogenous nanoparticles that can deliver biological information between cells
Dongmei Sun et al.
ADVANCED DRUG DELIVERY REVIEWS (2013)
Cooperation between Dmp1 Loss and Cydin D1 Overexpression in Breast Cancer
Sinan Zhu et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Directing HER4 mRNA expression towards the CYT2 isoform by antisense oligonucleotide decreases growth of breast cancer cells in vitro and in vivo
T. O. Nielsen et al.
BRITISH JOURNAL OF CANCER (2013)
Splicing therapy for neuromuscular disease
Andrew G. L. Douglas et al.
MOLECULAR AND CELLULAR NEUROSCIENCE (2013)
Synthetic nucleic acids delivered by exosomes: a potential therapeutic for generelated metabolic brain diseases
Rutao Liu et al.
METABOLIC BRAIN DISEASE (2013)
Challenging resistance mechanisms to therapies for metastatic melanoma
Lucio Tentori et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2013)
Reduction in serum clusterin is a potential therapeutic biomarker in patients with castration-resistant prostate cancer treated with custirsen
Brent Blumenstein et al.
CANCER MEDICINE (2013)
Phase I/II Trial of Custirsen (OGX-011), an Inhibitor of Clusterin, in Combination with a Gemcitabine and Platinum Regimen in Patients with Previously Untreated Advanced Non-small Cell Lung Cancer
Janessa J. Laskin et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
MDM4 is a key therapeutic target in cutaneous melanoma
Agnieszka Gembarska et al.
NATURE MEDICINE (2012)
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
Hector Peinado et al.
NATURE MEDICINE (2012)
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
Ryszard Kole et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
Corinne Betts et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2012)
A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer
Srikala S. Sridhar et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2011)
Randomized Phase II Trial of Custirsen (OGX-011) in Combination with Docetaxel or Mitoxantrone as Second-line Therapy in Patients with Metastatic Castrate-Resistant Prostate Cancer Progressing after First-line Docetaxel: CUOG Trial P-06c
Fred Saad et al.
CLINICAL CANCER RESEARCH (2011)
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Lydia Alvarez-Erviti et al.
NATURE BIOTECHNOLOGY (2011)
Position-dependent effects on stability in tricyclo-DNA modified oligonucleotide duplexes
Damian Ittig et al.
NUCLEIC ACIDS RESEARCH (2011)
A Phase I Trial of Oblimersen Sodium in Combination With Cisplatin and 5-Fluorouracil in Patients With Advanced Esophageal, Gastroesophageal Junction, and Gastric Carcinoma
Rachel Raab et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2010)
Alternative splicing: role of pseudoexons in human disease and potential therapeutic strategies
Ashish Dhir et al.
FEBS JOURNAL (2010)
Alternative pre-mRNA splicing regulation in cancer: pathways and programs unhinged
Charles J. David et al.
GENES & DEVELOPMENT (2010)
Randomized Phase II Study of Docetaxel and Prednisone With or Without OGX-011 in Patients With Metastatic Castration-Resistant Prostate Cancer
Kim N. Chi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Optimization of Peptide Nucleic Acid Antisense Oligonucleotides for Local and Systemic Dystrophin Splice Correction in the mdx Mouse
HaiFang Yin et al.
MOLECULAR THERAPY (2010)
Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer
C. N. Sternberg et al.
ANNALS OF ONCOLOGY (2009)
Spleen-specific suppression of TNF-α by cationic hydrogel-delivered antisense nucleotides for the prevention of arthritis in animal models
Lei Dong et al.
BIOMATERIALS (2009)
Phase I trial of GTI-2040, oxaliplatin, and capecitabine in the treatment of advanced metastatic solid tumors: a California Cancer Consortium Study
Stephen I. Shibata et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Phase II Trial of OGX-011 in Combination with Docetaxel in Metastatic Breast Cancer
Stephen Chia et al.
CLINICAL CANCER RESEARCH (2009)
LDH correlation with survival in advanced melanoma from two large, randomised trials (Oblimersen GM301 and EORTC 18951)
Sanjiv S. Agarwala et al.
EUROPEAN JOURNAL OF CANCER (2009)
Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells
Jing Wan et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
5-Year Survival in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia in a Randomized, Phase III Trial of Fludarabine Plus Cyclophosphamide With or Without Oblimersen
Susan O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping
Hans A. Heemskerk et al.
JOURNAL OF GENE MEDICINE (2009)
A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer A Study of the PMH Phase II Consortium
Natasha B. Leighl et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Phase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myeloma
Asher A. Chanan-Khan et al.
LEUKEMIA & LYMPHOMA (2009)
Functional and Evolutionary Insights into Human Brain Development through Global Transcriptome Analysis
Matthew B. Johnson et al.
NEURON (2009)
Locked nucleic acid as a novel class of therapeutic agents
Rakesh N. Veedu et al.
RNA BIOLOGY (2009)
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma
Barbara Pro et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
A phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer
Kim N. Chi et al.
CLINICAL CANCER RESEARCH (2008)
Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia
Rebecca B. Klisovic et al.
CLINICAL CANCER RESEARCH (2008)
Aberrant RNA splicing and its functional consequences in cancer cells
James D. Fackenthal et al.
DISEASE MODELS & MECHANISMS (2008)
A RNA antagonist of hypoxia-inducible factor-1α, EZN-2968, inhibits tumor cell growth
Lee M. Greenberger et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Effective exon skipping and restoration of dystrophin expression by peptide nucleic acid antisense oligonucleotides in mdx mice
Haifang Yin et al.
MOLECULAR THERAPY (2008)
Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides
Rudy Juliano et al.
NUCLEIC ACIDS RESEARCH (2008)
A phase I-II study of oblimersen sodium (G3139, Genasense) in combination with doxorubicin in advanced hepatocellular carcinoma (NCI # 5798)
J. J. Knox et al.
INVESTIGATIONAL NEW DRUGS (2008)
A Phase I/II study of GTI-2040 and capecitabine in patients with renal cell carcinoma
Walter M. Stadler et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Targeting the function of the HER2 oncogene in human cancer therapeutics
M. M. Moasser
ONCOGENE (2007)
Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript
Steve D. Wilton et al.
MOLECULAR THERAPY (2007)
Phase I trial of g3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: A Children's Oncology Group study
Susan R. Rheingold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Discovery of tissue-specific exons using comprehensive human exon microarrays
Tyson A. Clark et al.
GENOME BIOLOGY (2007)
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells
Hadi Valadi et al.
NATURE CELL BIOLOGY (2007)
Microbubble-enhanced ultrasound to deliver an antisense oligodeoxynucleotide targeting the human androgen receptor into prostate tumours
Petra Haag et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2006)
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group
Agop Y. Bedikian et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A Phase II study of Bcl-2 antisense (oblimersen sodium) combined with gemtuzumab ozogamicin in older patients with acute myeloid leukemia in first relapse
Joseph Moore et al.
LEUKEMIA RESEARCH (2006)
Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer
P Ritch et al.
LUNG CANCER (2006)
Antisense oligonucleotides: From design to therapeutic application
JHP Chan et al.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY (2006)
Phase III study of gemcitabine and cisplatin with or without aprinocarsen, a protein kinase C-alpha antisense oligonucleotide, in patients with advanced-stage non-sinall-cell lung cancer
L Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase I study of liposome-encapsulated c-raf antisense oligodeoxyribonucleotide infusion in combination with radiation therapy in patients with advanced malignancies
A Dritschilo et al.
CLINICAL CANCER RESEARCH (2006)
A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense™, G3139) and irinotecan in patients with metastatic colorectal cancer
MM Mita et al.
ANNALS OF ONCOLOGY (2006)
Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucteotide
S Fletcher et al.
JOURNAL OF GENE MEDICINE (2006)
Phase I to II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in patients with advanced chronic lymphocytic leukemia
SM O'Brien et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer
KN Chi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Phase II study of G3139, a Bcl-2 antisense oligonucleotide, in combination with dexamethasone and thalidomide in relapsed multiple myeloma patients
A Badros et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors
AA Desai et al.
ANNALS OF ONCOLOGY (2005)
Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: Pharmacokinetics, pharmacodynamics, and clinical activity
G Marcucci et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Safety and biologic activity of intravenous BCL-2 antisense oligonucleotide (G3139) and taxane chemotherapy in patients with advanced cancer
MJ Morris et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2005)
Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles
QL Lu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer
CM Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells
A Aartsma-Rus et al.
GENE THERAPY (2004)
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors:: A phase I study
CM Rudin et al.
CLINICAL CANCER RESEARCH (2004)
Genome-wide survey of human alternative pre-mRNA splicing with exon junction microarrays
JM Johnson et al.
SCIENCE (2003)
Antisense oligonucleotide-based therapeutics for cancer
NM Dean et al.
ONCOGENE (2003)
Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse
QL Lu et al.
NATURE MEDICINE (2003)
Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)
AM Oza et al.
GYNECOLOGIC ONCOLOGY (2003)
Antisense technologies - Improvement through novel chemical modifications
J Kurreck
EUROPEAN JOURNAL OF BIOCHEMISTRY (2003)
Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis
ND Brewis et al.
MOLECULAR THERAPY (2003)
Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia
G Marcucci et al.
BLOOD (2003)
VP22-mediated and light-activated delivery of an anti-c-raf1 antisense oligonucleotide improves its activity after intratumoral injection in nude mice
D Zavaglia et al.
MOLECULAR THERAPY (2003)
Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents
DR Mercatante et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Watson-Crick base-pairing properties of Tricyclo-DNA
D Renneberg et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2002)
A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer
CM Rudin et al.
ANNALS OF ONCOLOGY (2002)
Oligodeoxynucleotide-mediated inhibition of c-myb gene expression in autografted bone marrow:: a pilot study
SM Luger et al.
BLOOD (2002)
Gene delivery using ultrasound contrast agents
EC Unger et al.
ECHOCARDIOGRAPHY-A JOURNAL OF CARDIOVASCULAR ULTRASOUND AND ALLIED TECHNIQUES (2001)
Synthetic hydrogels as carriers in antisense therapy: Preliminary evaluation of an oligodeoxynucleotide covalent conjugate with a copolymer of 1-vinyl-2-pyrrolidinone and 2-hydroxyethyl methacrylate
X Lou et al.
JOURNAL OF BIOMATERIALS APPLICATIONS (2001)
The delivery of antisense therapeutics
S Akhtar et al.
ADVANCED DRUG DELIVERY REVIEWS (2000)
Messenger proteins: homeoproteins, TAT and others
A Prochiantz
CURRENT OPINION IN CELL BIOLOGY (2000)
Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain
A Khan et al.
JOURNAL OF DRUG TARGETING (2000)
Share Paper
